These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15371981)

  • 1. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori.
    Schwab M; Schaeffeler E; Klotz U; Treiber G
    Clin Pharmacol Ther; 2004 Sep; 76(3):201-9. PubMed ID: 15371981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
    J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].
    Asano M; Taniwaki H; Tsuji D; Sato Y; Shimizu T
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():450-3. PubMed ID: 16416832
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
    Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
    Isomoto H; Inoue K; Furusu H; Nishiyama H; Shikuwa S; Omagari K; Mizuta Y; Murase K; Murata I; Kohno S
    Helicobacter; 2003 Apr; 8(2):111-9. PubMed ID: 12662378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
    Furuta T; Shirai N; Xiao F; El-Omar EM; Rabkin CS; Sugimura H; Ishizaki T; Ohashi K
    Clin Gastroenterol Hepatol; 2004 Jan; 2(1):22-30. PubMed ID: 15017629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
    Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
    Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
    Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
    Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M
    Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
    Furuta T; Sugimoto M; Shirai N; Matsushita F; Nakajima H; Kumagai J; Senoo K; Kodaira C; Nishino M; Yamade M; Ikuma M; Watanabe H; Umemura K; Ishizaki T; Hishida A
    Aliment Pharmacol Ther; 2007 Sep; 26(5):693-703. PubMed ID: 17697203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Investigation about 3rd line eradication of H. pylori].
    Nakagawa S; Kato M; Shimizu Y; Nakagawa M; Asaka M
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():466-9. PubMed ID: 16363580
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.
    Furuta T; Shirai N; Kodaira M; Sugimoto M; Nogaki A; Kuriyama S; Iwaizumi M; Yamade M; Terakawa I; Ohashi K; Ishizaki T; Hishida A
    Clin Pharmacol Ther; 2007 Apr; 81(4):521-8. PubMed ID: 17215846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of non-response in Helicobacter pylori eradication trials.
    Klotz U; Treiber G; Schwab M
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1471. PubMed ID: 16105147
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success.
    Suzuki T; Matsuo K; Sawaki A; Wakai K; Hirose K; Ito H; Saito T; Nakamura T; Yamao K; Hamajima N; Tajima K
    Epidemiol Infect; 2007 Jan; 135(1):171-6. PubMed ID: 16740190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
    Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
    Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
    Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
    Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
    Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.